Viking Therapeutics Inc (VKTX) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Viking Therapeutics Inc stock $17.98, price $26.80, that is 32.9% below the price, quality 39 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $2.11 – $94.50 · fair‑value band $13.49 – $22.48 · the $26.80 price screens above the $17.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Follow Viking Therapeutics in your weekly email
Every Wednesday you see whether Viking Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Show moreShow less
Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
Stock analysis
Viking Therapeutics Inc (VKTX) currently trades at $26.80, while our estimate is $17.98, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $13.49 (bear) to $22.48 (bull), the price of $26.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Viking Therapeutics Inc reported revenue of $0 in FY2025 versus $10.7K in FY2021. Reported net income was −$360M in FY2025.
Key figures
Market cap $3.1B Mid · EPS (TTM) $−5.42 · Return on equity −96.4% · Return on assets (EBIT) −33.4% (5-year average) · Free cash flow −$279M · Net cash $166M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, VKTX screens richer than that median.
Fair Value
Bear$13.49Fair Value $17.98Bull$22.48
Price $26.80 · Downside -32.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality39/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth25
Are margins and returns getting better?
Cashflow59
Do the profits arrive as real cash?
Financial strength94
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility40
How calm the share price moves, does not count
Price momentum18
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 3 officers or directors sold shares worth $6.3M and none bought.
SaleMarianna ManciniChief Operating Officer2× since Jan 5, 2026: 75,878 shares, avg. $33.09$2.5MJul 29, 2026
SaleGreg ZanteChief Financial Officer2× since Jan 5, 2026: 78,878 shares, avg. $33.05$2.6MJul 29, 2026
SaleBrian LianPresident & CEO, Director2× since Jan 5, 2026: 381,926 shares, avg. $33.10$12.6MJul 29, 2026
BuyNeil William AubuchonChief Commercial Officer4,475 shares at $33.50$149,913Mar 10, 2026
SaleMatthew W FoehrDirector16,000 shares at $35.11$561,760Jan 2, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Viking's advancement of its dual GLP-1/GIP agonist into Phase 3 trials represents its core strength, while sustained negative cash flows and lack of any revenue form its chief weakness amid established rivals.
Main risk: Ongoing need for external financing to support Phase 3 development risks depleting cash resources and delaying any path to commercial revenue.
Viking is moving its dual GLP-1/GIP agonist into Phase 3 trials for an oral obesity treatment on the back of Phase 2 weight-loss results. As a clinical-stage company it still generates no revenue and reports large ongoing losses while facing established competitors. Our models see the shares as overvalued. Will the convenience of an oral option outweigh the long wait for data and the need for continued financing, or will rivals with approved products dominate the market?
Compare Viking Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Beats the industry median on 0/4 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Below median
Fair Value upside−32.9% · Below median
Profitability
Return on assets−50.3% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B4.86× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 1
FUTURE (revenue growth)0· sector 36
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Viking Therapeutics Inc (VKTX) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $17.98 versus a price of $26.80, about 33% lower (overvalued).
What is the fair value of VKTX?
Our estimate for Viking Therapeutics Inc is $17.98 (as of Nov 17, 2026), built from audited fundamentals. The current price: $26.80.
What is the quality score of VKTX?
Viking Therapeutics Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Viking Therapeutics Inc (VKTX)?
Our calculated price target is the estimate of $17.98 (as of Nov 17, 2026). Cautious scenario $13.49, optimistic scenario $22.48. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Viking Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $17.98, about 33% lower versus a price of $26.80 (overvalued). Cautious scenario $13.49, optimistic scenario $22.48. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Viking Therapeutics Inc (VKTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Viking Therapeutics Inc it is $17.98 per share (as of Nov 17, 2026), against a price of $26.80.
Is Viking Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, VKTX trades above its calculated fair value: price $26.80, fair value $17.98, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VKTX?
No. The price is what the market pays today ($26.80); the fair value is what the company's own numbers justify ($17.98). For Viking Therapeutics Inc the two are $8.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Viking Therapeutics Inc worth?
The market values Viking Therapeutics Inc at about $3.1B (market capitalisation, as of Nov 17, 2026). Per share that is $26.80; our models calculate a fair value of $17.98 per share.
What do the bullish and bearish scenarios say about VKTX?
Our models span a range for Viking Therapeutics Inc: cautious scenario $13.49, base $17.98, optimistic $22.48 per share (as of Nov 17, 2026, price $26.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Viking Therapeutics Inc (VKTX)?
Balance-sheet figures for Viking Therapeutics Inc (as of Nov 17, 2026): return on equity −96.4%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is VKTX from its 52-week high?
Viking Therapeutics Inc trades at $26.80, about 36% below its 52-week high of $42.13 and 11% above the low of $24.21 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $17.98 is for.
Which stocks are comparable to Viking Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Viking Therapeutics Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $26.80, calculated fair value $17.98 (−33%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Viking Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Viking Therapeutics Inc (VKTX)?
The closing price on Nov 16, 2026 was $26.80. Our estimate is $17.98, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Viking Therapeutics Inc right now?
The price sits above even our optimistic bull case ($22.48). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Viking Therapeutics Inc
How large is the market capitalisation of Viking Therapeutics Inc (VKTX)?
The market capitalisation of Viking Therapeutics Inc is $3.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Viking Therapeutics Inc (VKTX)?
Earnings per share at Viking Therapeutics Inc are $−5.42. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Viking Therapeutics Inc (VKTX)?
The return on equity (ROE) of Viking Therapeutics Inc is −96.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Viking Therapeutics Inc (VKTX)?
On an EBIT basis the return on assets of Viking Therapeutics Inc is −33.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Viking Therapeutics Inc (VKTX) generate?
The free cash flow of Viking Therapeutics Inc is −$279M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Viking Therapeutics Inc (VKTX) hold?
Viking Therapeutics Inc holds more cash than debt, $166M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Viking Therapeutics Inc in the live analysis
One click puts Viking Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.